Venus Remedies Limited (VENUSREM.NS)
INR 301.1
(2.4%)
INR 301.1
(2.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.26 Billion INR | 4.28% |
| 2022 | 6.01 Billion INR | 3.67% |
| 2021 | 5.79 Billion INR | 4.31% |
| 2020 | 5.55 Billion INR | -12.84% |
| 2019 | 6.37 Billion INR | -12.98% |
| 2018 | 7.32 Billion INR | -2.4% |
| 2017 | 7.5 Billion INR | -9.44% |
| 2016 | 8.29 Billion INR | -1.63% |
| 2015 | 8.42 Billion INR | 0.21% |
| 2014 | 8.41 Billion INR | 0.8% |
| 2013 | 8.34 Billion INR | 16.28% |
| 2012 | 7.17 Billion INR | 25.0% |
| 2011 | 5.74 Billion INR | 24.56% |
| 2010 | 4.6 Billion INR | 31.64% |
| 2009 | 3.5 Billion INR | 18.0% |
| 2008 | 2.96 Billion INR | 42.58% |
| 2007 | 2.08 Billion INR | 33.76% |
| 2006 | 1.55 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 6.6 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 6.26 Billion INR | 4.28% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 6.4 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 6.26 Billion INR | 0.0% |
| 2022 FY | 6.01 Billion INR | 3.67% |
| 2022 Q4 | 6.01 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 5.82 Billion INR | 0.0% |
| 2021 Q2 | 6.07 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 5.79 Billion INR | 4.31% |
| 2021 Q4 | 5.79 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 5.52 Billion INR | 0.0% |
| 2020 FY | 5.55 Billion INR | -12.84% |
| 2020 Q4 | 5.55 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 6.37 Billion INR | -12.98% |
| 2019 Q2 | 7.06 Billion INR | 0.0% |
| 2019 Q4 | 6.37 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 7.32 Billion INR | -2.4% |
| 2018 Q4 | 7.32 Billion INR | 0.0% |
| 2017 FY | 7.5 Billion INR | -9.44% |
| 2016 FY | 8.29 Billion INR | -1.63% |
| 2016 Q4 | 8.29 Billion INR | 0.0% |
| 2015 FY | 8.42 Billion INR | 0.21% |
| 2014 FY | 8.41 Billion INR | 0.8% |
| 2013 FY | 8.34 Billion INR | 16.28% |
| 2013 Q4 | 8.34 Billion INR | 0.0% |
| 2012 Q2 | 1.29 Billion INR | 0.0% |
| 2012 FY | 7.17 Billion INR | 25.0% |
| 2012 Q4 | 7.17 Billion INR | 0.0% |
| 2011 FY | 5.74 Billion INR | 24.56% |
| 2010 FY | 4.6 Billion INR | 31.64% |
| 2009 FY | 3.5 Billion INR | 18.0% |
| 2008 FY | 2.96 Billion INR | 42.58% |
| 2007 FY | 2.08 Billion INR | 33.76% |
| 2006 FY | 1.55 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aarti Drugs Limited | 24.32 Billion INR | 74.23% |
| Albert David Limited | 4.97 Billion INR | -25.872% |
| Alembic Limited | 23.28 Billion INR | 73.083% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1231.338% |
| Hester Biosciences Limited | 6.62 Billion INR | 5.362% |
| Hikal Limited | 24.87 Billion INR | 74.797% |
| Ind-Swift Limited | 6.54 Billion INR | 4.223% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -161.112% |
| Unichem Laboratories Limited | 31.69 Billion INR | 80.222% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 90.275% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -324.447% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 18.075% |
| Brooks Laboratories Limited | 904.45 Million INR | -593.048% |
| Eris Lifesciences Limited | 70.48 Billion INR | 91.107% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 73.288% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -188.758% |
| Wanbury Limited | 3.43 Billion INR | -82.487% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 75.724% |
| Alkem Laboratories Limited | 155.74 Billion INR | 95.975% |
| FDC Limited | 24.68 Billion INR | 74.603% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 78.009% |
| Gufic Biosciences Limited | 10.92 Billion INR | 42.626% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 46.2% |
| Innova Captab Limited | 13.2 Billion INR | 52.545% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 72.071% |
| Ipca Laboratories Limited | 111.01 Billion INR | 94.354% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 94.572% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 10.49% |
| Lupin Limited | 239.97 Billion INR | 97.388% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -87.998% |
| Medico Remedies Limited | 961.95 Million INR | -551.622% |
| Morepen Laboratories Limited | 12.93 Billion INR | 51.529% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 71.391% |
| Orchid Pharma Limited | 15.53 Billion INR | 59.66% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 21.09% |
| RPG Life Sciences Limited | 5.12 Billion INR | -22.22% |
| Sigachi Industries Limited | 6.94 Billion INR | 9.699% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.267% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 72.191% |
| Themis Medicare Limited | 5.66 Billion INR | -10.666% |
| Vaishali Pharma Limited | 799.55 Million INR | -683.972% |
| Windlas Biotech Limited | 6.26 Billion INR | -0.1% |
| ZIM Laboratories Limited | 4.46 Billion INR | -40.286% |
| Sakar Healthcare Limited | 3.88 Billion INR | -61.28% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.609% |
| Divi's Laboratories Limited | 154.7 Billion INR | 95.948% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 41.854% |
| Mankind Pharma Limited | 119.63 Billion INR | 94.76% |
| Sequent Scientific Limited | 15.4 Billion INR | 59.307% |
| Laurus Labs Limited | 83.87 Billion INR | 92.526% |
| Neuland Laboratories Limited | 18.32 Billion INR | 65.795% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 84.306% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 95.634% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 97.859% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -70.859% |
| Wockhardt Limited | 76.49 Billion INR | 91.805% |
| Bal Pharma Limited | 3.2 Billion INR | -95.647% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.382% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 48.361% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -516.891% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 76.762% |
| Shilpa Medicare Limited | 30.93 Billion INR | 79.735% |
| Valiant Laboratories Limited | 3.42 Billion INR | -82.916% |
| Ajanta Pharma Limited | 46.38 Billion INR | 86.486% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -105.523% |
| Granules India Limited | 55.2 Billion INR | 88.646% |
| Medicamen Biotech Limited | 2.94 Billion INR | -112.829% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -54.901% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.241% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 95.838% |
| NATCO Pharma Limited | 69.06 Billion INR | 90.924% |
| Suven Life Sciences Limited | 2.84 Billion INR | -120.015% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -251.806% |
| Strides Pharma Science Limited | 58.39 Billion INR | 89.266% |
| Indoco Remedies Limited | 21.44 Billion INR | 70.773% |
| Alpa Laboratories Limited | 1.82 Billion INR | -243.24% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -315.48% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -21.705% |